Detalhe da pesquisa
1.
Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Semin Arthritis Rheum
; 48(3): 467-474, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29555348